Anthrax - An overview

Medical Science Monitor

Volumn 9, Issue 11, 2003, Pages

  Öncü, Serkan ^a   Öncü, Selcen ^a   Sakarya, Serhan ^a  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

Author keywords

Anthrax; B.anthracis; Bioterrorism

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTHRAX LETHAL FACTOR; ANTHRAX TOXIN; ANTIBIOTIC AGENT; AZTREONAM; BACTERIAL PROTEIN; BETA LACTAMASE; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DOXYCYCLINE; EDEMA FACTOR; IMIPENEM; PENICILLIN G; PROTECTIVE ANTIGEN; QUINOLONE DERIVATIVE; RIFAMPICIN; SULFAMETHOXAZOLE; TRIMETHOPRIM; UNCLASSIFIED DRUG; VANCOMYCIN; VIRULENCE FACTOR;

ANTHRAX; ANTIBIOTIC THERAPY; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; BRONCHOPNEUMONIA; CLINICAL FEATURE; COLLAPSE; DEATH; ENTERITIS; HUMAN; INCIDENCE; INFECTION PREVENTION; INTOXICATION; NONHUMAN; PATHOGENESIS; REVIEW; SEPTICEMIA;

ANIMALS; ANTHRAX; BACILLUS ANTHRACIS; BIOTERRORISM; HUMANS;

EID: 1642483597     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Mock M, Fouet A: Anthrax. Annu Rev Microbiol, 2001; 55: 647-71
2. Boutiba-Ben Boubaker I, Ben Redjeb S: [Bacillus anthracis: causative agent of anthrax]. Tunis Med, 2001; 79: 642-6
3. Jedrzejas M: Three dimensional structure and molecular mechanism of novel enzymes of spore forming bacteria. Med Sci Monit, 2002; 8: RA183-90
4. Hart CA, Beeching NJ: A spotlight on anthrax. Clin Dermatol, 2002; 20: 365-75
5. Dirckx JH: Virgil on anthrax. Am J Dermatopathol, 1981; 3: 191-5
6. Turnbull PC: Introduction: anthrax history, disease and ecology. Curr Top Microbiol Immunol, 2002; 271: 1-19
7. Hugh-Jones M: 1996-97 Global Anthrax Report. J Appl Microbiol, 1999; 87: 189-91
8. Brachman PS: Bioterrorism: an update with a focus on anthrax. Am J Epidemiol, 2002; 155: 981-7
9. Mal'tseva AN: [The epidemiology and prevention of anthrax]. Feldsher Akush, 1990; 55: 10-4
10. Watson A, Keir D: Information on which to base assessments of risk from environment, contaminated with anthrax spores. Epidemiol Infect, 1994; 113: 479-90
11. Davies JC: A major epidemic of anthrax in Zimbabwe. Cent Afr J Med, 1982; 28: 291-8
12. Cieslak TJ, Eitzen EM Jr. Clinical and epidemiologic principles of anthrax. Emerg Infect Dis, 1999; 5: 552-5
13. Kaya A, Tasyaran MA, Erol S, Ozkurt Z, Ozkan B: Anthrax in adults and children: a review of 132 cases in Turkey. Eur J Clin Microbiol Infect Dis, 2002; 21: 258-61
14. Bales ME, Dannenberg AL, Brachman PS, Kaufmann AF, Klatsky PC, Ashford DA: Epidemiologic response to anthrax outbreaks: field investigations, 1950-2001. Emerg Infect Dis, 2002; 8: 1163-74
15. Schmid G, Kaufmann A: Anthrax in Europe: its epidemiology, clinical characteristics, and role in bioterrorism. Clin Microbiol Infect, 2002; 8: 479-88
16. Davies JC: A major epidemic of anthrax in Zimbabwe. Part II. Cent Afr J Med, 1983; 29: 8-12
17. Davies JC: A major epidemic of anthrax in Zimbabwe. The experience at the Beatrice Road Infections Diseases Hospital, Harare. Cent Afr J Med, 1985; 31: 176-80
18. Aldhous P: Biological warfare. Gruinard Island handed back. Nature, 1990; 344: 801
19. Manchee RJ, Broster MG, Anderson IS, Henstridge RM, Melling J: Decontamination of Bacillus anthracis on Gruinard Island? Nature, 1983; 303: 239-40
20. Manchee RJ, Broster MG, Henstridge RM, Stagg AJ, Melling J: Anthrax island. Nature, 1982; 296: 598
21. Manchee RJ, Broster MG, Melling J, Henstridge RM, Stagg AJ: Bacillus anthracis on Gruinard Island. Nature, 1981; 294: 254-5
22. Bezdenezhnykh IS, Nikiforov VN: [Epidemiologic analysis of anthrax in Sverdlovsk]. Zh Mikrobiol Epidemiol Immunobiol, 1980: 111-3
23. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH: Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A, 1993; 90: 2291-4
24. Meselson M, Guillemin J, Hugh Jones M et al: The Sverdlovsk anthrax outbreak of 1979. Science, 1994; 266: 1202-8
25. Jefferson T, Demicheli V, Deeks J, et al: Vaccines for preventing anthrax. Cochrane Database Syst Rev, 2000: CD000975
26. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices. J Toxicol Clin Toxicol, 2001; 39: 85-100
27. Turner AJ, Galvin JW, Rubira RJ, et al: Experiences with vaccination and epidemiological investigations on an anthrax outbreak in Australia in 1997. J Appl Microbiol, 1999; 87: 294-7
28. Turnbull PC: Definitive identification of Bacillus anthracis - a review. J Appl Microbiol, 1999; 87: 237-40
29. Penn CC, Klotz S: Anthrax. In: Gorbach LS BJ, Blacklow NR, ed. Infectious Diseases. Philadelphia: W.B. Saunders Company, 1998: 1575-78
30. Brossier F, Weber Levy M, Mock M, Sirard JC: Role of toxin functional domains in anthrax pathogenesis. Infect Immun, 2000; 68: 1781-6
31. Mansour-Ghanaei F, Zareh S, Salimi A: GI anthrax: report of one case confirmed with autopsy. Med Sci Monit, 2002; 8: CS73-6
32. Kwong KL, Que TL, Wong SN, So KT: Fatal meningoencephalitis due to Bacillus anthracis. J Paediatr Child Health, 1997; 33: 539-41
33. Bradley KA, Mogridge J, Mourez M, et al: Identification of the cellular receptor for anthrax toxin. Nature, 2001; 414: 225-9
34. Makino S, Watarai M, Cheun HI, et al: Effect of the lower molecular capsule released from the cell surface of Bacillus anthracis on the pathogenesis of anthrax. J Infect Dis, 2002; 186: 227-33
35. Mourez M, Lacy DB, Cunningham K et al: 2001: a year of major advances in anthrax toxin research. Trends Microbiol, 2002; 10: 287-93
36. Brossier F, Guidi-Rontani C, Mosk M: [Anthrax toxins]. C R Seances Soc Biol Fil, 1998; 192: 437-44
37. Bradley KA, Young JA: Anthrax toxin receptor proteins. Biochem Pharmacol, 2003; 65: 309-14
38. Drum CL, Yan SZ, Bard J et al: Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. Nature, 2002; 415: 396-402
39. Human anthrax associated with an epizootic among livestock - North Dakota, 2000. MMWR Morb Mortal Wkly Rep, 2001; 50: 677-80
40. Caksen H, Arabaci F, Abuhandan M, Tuncer O, Cesur Y: Cutaneous anthrax in eastern Turkey. Cutis, 2001; 67: 488-92
41. Oncul O, Ozsoy MF, Gul HC, et al: Cutaneous anthrax in Turkey: a review of 32 cases. Scand J Infect Dis, 2002; 34: 413-6
42. Khajehdehi P: Toxemic shock, hematuria, hypokalemia, and hypoproteinemia in a case of cutaneous anthrax. Mt Sinai J Med, 2001; 68: 213-5
43. Doganay M, Bakir M, Dokmetas I: A case of cutaneous anthrax with toxaemic shock. Br J Dermatol, 1987; 117: 659-62
44. Coban YK, Balik O, Boran C: Cutaneous anthrax of the hand and its reconstruction with a reverse flow radial forearm flap. Ann Plast Surg, 2002; 49: 109-11
45. Brook I: The prophylaxis and treatment of anthrax. Int J Antimicrob Agents, 2002; 20: 320-5
46. Bartlett JG, Inglesby TV, Jr, Borio L: Management of anthrax. Clin Infect Dis, 2002; 35: 851-8
47. Carucci JA, McGovern TW, Norton SA et al: Cutaneous anthrax management algorithm. J Am Acad Dermatol, 2002; 47: 766-9
48. Swartz MN: Recognition and management of anthrax - an update. N Engl J Med, 2001; 345: 1621-6
49. Plotkin SA, Brachman PS, Utell M, et al: An epidemic of inhalation anthrax, the first in the twentieth century: I. Clinical features. 1960. Am J Med, 2002; 112: 4-12; discussion 2-3
50. Henry L: Inhalational anthrax: threat, clinical presentation, and treatment. J Am Acad Nurse Pract, 2001; 13: 164-8; quiz 169-70
51. Kuehnert MJ, Doyle TJ, Hill HA et al: Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses. Clin Infect Dis, 2003; 36: 328-36
52. Krol CM, Uszynski M, Dillon EH et al: Dynamic CT features of inhalational anthrax infection. AJR Am J Roentgenol, 2002; 178: 1063-6
53. Earls JP, Cerva D, Jr, Berman E et al: Inhalational anthrax after bioterrorism exposure: spectrum of imaging findings in two surviving patients. Radiology, 2002; 222: 305-12
54. Lakshmi N, Kumar AG: An epidemic of human anthrax - a study. Indian J Pathol Microbiol, 1992; 35: 1-4
55. Sirisanthana T, Navachareon N, Tharavichitkul P, Sirisanthana V, Brown AE: Outbreak of oral oropharyngeal anthrax: an unusual manifestation of human infection with Bacillus anthracis. Am J Trop Med Hyg, 1984; 33: 144-50
56. Tasyaran MA, Deniz O, Ertek M, Cetin K: Anthrax meningitis: case report and review. Scand J Infect Dis, 2002; 34: 66-7
57. Durst UN, Bartenstein J, Buhlmann H, et al: [Anthrax meningitis]. Schweiz Med Wochenschr, 1986; 116: 1222-8
58. Mahfoudh A, Mattoussi N, Karray A et al: [Renal anthrax a case report in a child]. Tunis Med, 1993; 71: 231-5
59. Regadera Sejas FJ, Sanchez Trilla A, Alonso Sainz F: [Renal anthrax. Apropos of 3 cases]. Arch Esp Urol, 1983; 36: 433-8
60. Celebi S, Aykan U, Alagoz G, Esmerligil S: Palbebral anthrax. Eur J Ophthalmol, 2001; 11: 171-4
61. Miller JM: Agents of bioterrorism. Preparing for bioterrorism at the community health care level. Infect Dis Clin North Am, 2001; 15: 1127-56
62. Shlyakhov E, Rubinstein E: Evaluation of the anthraxin skin test for diagnosis of acute and past human anthrax. Eur J Clin Microbiol Infect Dis, 1996; 15: 242-5
63. Turnbull PC, Doganay M, Lindeque PM, et al: Serology and anthrax in humans, livestock and Etosha National Park wildlife. Epidemiol Infect, 1992; 108: 299-313
64. Harrison LH, Ezzell JW, Abshire TG, et al: Evaluation of serologic tests for diagnosis of anthrax after an outbreak of cutaneous anthrax in Paraguay. J Infect Dis, 1989; 160: 706-10
65. Turnbull PC, Broster MG, Carman JA, et al: Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun, 1986; 52: 356-63
66. Makino SI, Cheun HI, Watarai M, Uchida I, Takeshi K: Detection of anthrax spores from the air by real time PCR. Lett Appl Microbiol, 2001; 33: 237-40
67. Update: Investigation of anthrax associated with intentional exposure and interim public health guidelines, October, 2001. MMWR Morb Mortal Wkly Rep, 2001; 50: 889-93
68. Borg MA, Tieck WC, Jr. Responding to anthrax. J Dent Technol, 2001; 18: 12-4, 28
69. Lalitha MK, Thomas MK: Penicillin resistance in Bacillus anthracis. Lancet, 1997; 349: 1522
70. Cavallo JD, Ramisse F, Girardet M, Vaissaire J, Mock M, Hernandez E: Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000. Antimicrob Agents Chemother, 2002; 46: 2307-9
71. Chen Y, Succi J, Tenover FC, Koehler TM: Beta-lactamase genes of the penicillin susceptible Bacillus anthracis Sterne strain. J Bacteriol, 2003; 185: 823-30
72. Mohammed MJ, Marston CK, Popovic T, et al: Antimicrobial susceptibility testing of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods. J Clin Microbiol, 2002; 40, 1902-7
73. Bradaric N, Punda-Polic V: Cutaneous anthrax due to penicillin resistant Bacillus anthracis transmitted by an insect bite. Lancet, 1992; 340: 306-7
74. Ressel G: CDC updates interim guidelines for anthrax exposure management and antimicrobial therapy. Am Fam Physician, 2001; 64: 1901-2, 1904
75. Inglesby TV, O'Toole T, Henderson DA et al: Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA, 2002; 287: 2236-52
76. Bryskier A: Bacillus anthracis and antibacterial agents. Clin Microbiol Infect, 2002; 8: 467-78
77. From the Centers for Disease Control and Prevention. Recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. JAMA, 2001; 286: 2663-4
78. Meyerhoff A, Murphy D: Guidelines for treatment of anthrax. JAMA, 2002; 288: 1848-9; author reply 1848-9
79. Friedlander AM, Welkos SL, Ivins BE: Anthrax vaccines. Curr Top Microbiol Immunol, 2002; 271: 33-60
80. Friedlander AM, Pittman PR, Parker GW: Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAMA, 1999;282:2104-6
81. Wasserman GM, Grabenstein JD, Pittman PR et al: Analysis of adverse events after anthrax immunization in US Army medical personnel. J Occup Environ Med, 2003; 45: 222-33
82. Enstone JE, Wale MC, Nguyen Van Tam JS, Pearson JC: Adverse medical events in British service personnel following anthrax vaccination. Vaccine, 2003; 21: 1348-54
83. King P: Recognition and management of anthrax. N Engl J Med, 2002; 346: 943-5; author reply 943-5
84. Post-exposure anthrax prophylaxis. Conn Med, 2001; 65: 721-2
85. Update: Investigation of bioterrorism related anthrax, 2001. MMWR Morb Mortal Wkly Rep, 2001; 50: 1008-10
86. Jernigan DB, Raghunathan PL, Bell BP et al: Investigation of bioterrorism related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis, 2002; 8: 1019-28